Skip to main content

Biosystemix to Analyze Data for S2K to Find Predictive Disease Markers

NEW YORK, June 21 (GenomeWeb News) - Biosystemix will develop computational models based on genomic and proteomic data for S2K, a Canadian consortium of researchers, the company said today.

 

Under the partnership, Biosystemix of Kingston, Canada, will use its data mining algorithms to discover predictive molecular markers and models from gene expression, proteomics, and cellular immune response data generated by S2K in the areas of HIV, HCV, rheumatoid arthritis, and transplant rejection.

 

Intellectual property resulting from the analyses will form the basis for commercial products such as diagnostic and prognostic markers, according to the company.

 

S2K's program, "Functional Genomics, Pharmacogenomics and Proteomics of the Immune Response in Health and Immune Related Disorders", is funded by Genome Canada and Genome Quebec.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.